Astragaloside positively regulated osteogenic differentiation of pre-osteoblast MC3T3-E1 through PI3K/Akt signaling pathway

Wei, Jing; Ji, Hongjuan; Jiang, Rui; Wang, Jinlong

doi:10.1186/s13018-021-02690-1

Cited by 13 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the process of osteogenic differentiation of BMSCs, the ALP enzyme is active in the early stage . With the passage of time, the activity of ALP decreases, while the calcium nodules gradually come into formation. , Therefore, in the late stage of the BMSC osteogenesis process, the osteogenic activity of BMSCs can be better reflected by detecting the formation of calcium nodules. Moreover, judging the osteogenic ability of BMSCs can also be achieved by detecting osteogenesis-related genes and osteogenesis-related proteins by PCR and WB experiments, respectively.…”

Section: Resultsmentioning

confidence: 99%

Janus-Inspired Core–Shell Structure Hydrogel Programmatically Releases Melatonin for Reconstruction of Postoperative Bone Tumor

Huang

Zhao

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

At present, surgery is one of the main treatments for bone tumor. However, the risk of recurrence and the large area of bone defects after surgery pose a great challenge. Therefore, a Janus-inspired core–shell structure bone scaffold was designed to achieve the self-programmed release of melatonin at different concentrations, clearing the residual tumor cells at early stage after resection and promoting bone repair later. The layered differential load designs inspired by Janus laid the foundation for the differential release of melatonin, where sufficient melatonin inhibited tumor growth as low dose promoted osteogenesis. Then, the automatically programmed delivery of melatonin is achieved by the gradient degradation of the core–shell structure. In the material characterization, scanning electron microscopy revealed the core–shell structure. The drug release experiment and in vivo degradation experiment reflected the programmed differential release of melatonin. In the biological experiment part, in vivo and in vitro experiments not only confirmed the significant inhibitory effect of the core–shell hydrogel scaffold on tumor but also confirmed its positive effect on osteogenesis. Our Janus-inspired core–shell hydrogel scaffold provides a safe and efficient means to inhibit tumor recurrence and bone repair after bone tumor, and it also develops a new and efficient tool for differential and programmed release of other drugs.

show abstract

Section: Resultsmentioning

confidence: 99%

Janus-Inspired Core–Shell Structure Hydrogel Programmatically Releases Melatonin for Reconstruction of Postoperative Bone Tumor

Huang

Zhao

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…For instance, astragaloside is implicated with the osteogenic differentiation of pre-osteoblast MC3T3-E1 in osteoporosis via mediating the PI3K/Akt signaling pathway. 24 Neohesperidin participates in bone mesenchymal stem cells' osteogenic differentiation through adjusting the Wnt/βcatenin signaling pathway in osteoporosis. 25 Arbutin modulates autophagy in osteoblasts to suppress the glucocorticoid-triggered osteoporosis.…”

Section: Discussionmentioning

confidence: 99%

“…Early studies have illuminated that there were a variety of herbs involved in the development of osteoporosis. For instance, astragaloside is implicated with the osteogenic differentiation of pre‐osteoblast MC3T3‐E1 in osteoporosis via mediating the PI3K/Akt signaling pathway 24 . Neohesperidin participates in bone mesenchymal stem cells' osteogenic differentiation through adjusting the Wnt/β‐catenin signaling pathway in osteoporosis 25 .…”

Section: Discussionmentioning

confidence: 99%

Casticin promotes osteogenic differentiation of bone marrow stromal cells and improves osteoporosis in rats by regulating nuclear factor‐κB/mitogen‐activated protein kinase

Zhang

et al. 2022

Int J of Rheum Dis

View full text Add to dashboard Cite

Background Osteoporosis has influenced millions of people, especially postmenopausal women, which has become a big burden to the whole world. Although the diverse roles of casticin (CAS) on different diseases were identified, whether it was implicated with osteoporosis was unknown. Methods A rat model of osteoporosis was established through dexamethasone (DEX) treatment and a cell model reflecting the osteogenic and osteoclast induction was constructed in bone marrow stromal cells (BMSCs). The calcification at the late stage of induction was measured via Alizarin Red S staining. Western blot was applied to evaluate the levels of proteins. Results Hematoxylin and eosin staining revealed that the number of bone trabecular in DEX‐induced osteoporosis rats was decreased, while increased doses of CAS treatment elevated the number of bone trabecular. CAS treatment alleviated DEX‐induced osteoporosis in rats. Moreover, we found that CAS inhibited the nuclear factor‐κB/mitogen‐activated protein kinase (NF‐κB/MAPK) pathway. In addition, CAS promoted osteogenic differentiation of BMSCs and reduced osteoclastogenesis of bone marrow monocytes. Finally, CAS was observed to retard the receptor activator of NFκ‐B ligand‐induced NF‐κB/MAPK pathway. Conclusion CAS promoted osteogenic differentiation of BMSCs and improved osteoporosis in rats by regulating the NF‐κB/MAPK pathway. This might shed a light into using CAS as a drug treating osteoporosis in the future.

show abstract

“…In osteoporosis, the PI3K/Akt signaling cascade is triggered, which performs a fundamental function in the osteoclast’s hyperactivation as well as the differentiation and maturation of osteoblasts ( Han et al, 2021 ). Astragaloside positively regulated osteogenic differentiation of MC3T3-E1 by triggering the PI3K/Akt signaling pathway ( Jing et al, 2021 ). Research has found that dexamethasone inhibits the osteogenic differentiation of osteoblasts in vivo and in vitro via the PI3K/Akt signaling pathway ( Pan et al, 2019 ).…”

Section: Discussionmentioning

confidence: 99%

Epimedin C Alleviates Glucocorticoid-Induced Suppression of Osteogenic Differentiation by Modulating PI3K/AKT/RUNX2 Signaling Pathway

Chen

Huang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Secondary osteoporosis is triggered mostly by glucocorticoid (GC) therapy. Dexamethasone (DEX) was reported to inhibit osteogenic differentiation in zebrafish larvae and MC3T3-E1 cells in prior research. In this research, we primarily examined the protective impacts of epimedin C on the osteogenic inhibition impact of MC3T3-E1 cells and zebrafish larvae mediated by DEX. The findings illustrated no apparent toxicity for MC3T3-E1 cells after administering epimedin C at increasing dosages from 1 to 60 μM and no remarkable proliferation in MC3T3-E1 cells treated using DEX. In MC3T3-E1 cells that had been treated using DEX, we discovered that epimedin C enhanced alkaline phosphatase activities and mineralization. Epimedin C could substantially enhance the protein expression of osterix (OSX), Runt-related transcription factor 2 (RUNX2), and alkaline phosphatase (ALPL) in MC3T3-E1 cells subjected to DEX treatment. Additionally, epimedin C stimulated PI3K and AKT signaling pathways in MC3T3-E1 cells that had been treated using DEX. Furthermore, in a zebrafish larvae model, epimedin C was shown to enhance bone mineralization in DEX-mediated bone impairment. We also found that epimedin C enhanced ALPL activity and mineralization in MC3T3-E1 cells treated using DEX, which may be reversed by PI3K inhibitor (LY294002). LY294002 can also reverse the protective impact of epimedin C on DEX-mediated bone impairment in zebrafish larval. These findings suggested that epimedin C alleviated the suppressive impact of DEX on the osteogenesis of zebrafish larval and MC3T3-E1 cells via triggering the PI3K and AKT signaling pathways. Epimedin C has significant potential in the development of innovative drugs for the treatment of glucocorticoid-mediated osteoporosis.

show abstract

Astragaloside positively regulated osteogenic differentiation of pre-osteoblast MC3T3-E1 through PI3K/Akt signaling pathway

Cited by 13 publications

References 29 publications

Janus-Inspired Core–Shell Structure Hydrogel Programmatically Releases Melatonin for Reconstruction of Postoperative Bone Tumor

Janus-Inspired Core–Shell Structure Hydrogel Programmatically Releases Melatonin for Reconstruction of Postoperative Bone Tumor

Casticin promotes osteogenic differentiation of bone marrow stromal cells and improves osteoporosis in rats by regulating nuclear factor‐κB/mitogen‐activated protein kinase

Epimedin C Alleviates Glucocorticoid-Induced Suppression of Osteogenic Differentiation by Modulating PI3K/AKT/RUNX2 Signaling Pathway

Contact Info

Product

Resources

About